Diabetes Genes

TriMaster

Lead Site, CI

Study Team & Contact Details

Chief Investigator
Professor Andrew Hattersley
a.t.hattersley@exeter.ac.uk

University of Exeter, and Royal Devon and Exeter NHS Foundation Trust

Trial Manager
Catherine Angwin 01392 408185
c.angwin@exeter.ac.uk

Study Team
Caroline Jenkinson 01392 408179
Claire Thorne 01392 408180
Nina Rickards 01392 408186
rde-tr.diabetesdrugresponse@nhs.net

Lead Nurse
Kim Rowden 01392 408181

Study Refs

REC: SC/16/0147

IRAS:  83044

MHRA: 2015-002790-38

ClinicalTrials.gov: NCT02653209

ISRCTN: ISRCTN12039221

Funder: Medical Research Council (MRC) MR/N00633X/1

A research study to help improve treatment of type 2 diabetes, by learning how individuals respond to different blood sugar-lowering drugs




Inclusion criteria

  1. Clinical diagnosis of Type 2 diabetes
  2. Age ≥30 and ≤80
  3. Currently treated with either metformin alone or two classes of oral glucose-lowering therapy (given either as separate or combined medications), that do not include a DPP4-inhibitor, a SGLT2-inhibitor or a thiazolidinedione.
  4. Diabetes duration ≥ 12 months
  5. No change in diabetes treatment (new treatments or dose change) within previous 3 months
  6. HbA1c > 58mmol/mol (7.5%) and ≤110mmol/mol (12.2%)
  7. eGFR ≥ 60mls/min/1.73m²
  8. Able and willing to give informed consent

FUNDERS